NCCN Guidelines® Insights - B-Cell Lymphomas, Version 6.2023

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas.

NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
NCCN Guidelines® Insights - Breast Cancer Screening and Diagnosis, Version 1.2023
The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.
NCCN Guidelines® Insights - Survivorship, Version 1.2023
These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.
NCCN Guidelines® Insights - Biliary Tract Cancers, Version 2.2023
The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.
NCCN Guidelines® Insights - Breast Cancer, Version 4.2023

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly.

NCCN Guidelines® Insights - Distress Management, Version 2.2023
All patients experience some level of distress associated with a cancer diagnosis and the effects of the disease and its treatment regardless of the stage of disease. Clinically significant levels of distress occur in a subset of patients, and identification and treatment of distress are of utmost importance. These NCCN Guidelines Insights describe updates to the NCCN Distress Thermometer and Problem List, and to the treatment algorithms for patients with trauma- and stressor-related disorders.
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2023

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC.

NCCN Guidelines® Insights - Prostate Cancer Early Detection, Version 1.2023
These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
NCCN Guidelines® Insights - Hematopoietic Cell Transplantation, Version 3.2022
These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Cell Transplantation (HCT), including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

Pages

Subscribe to RSS - Monograph/Journal Supplement